PL3068414T3 - Kompozycje i sposoby użyteczne w leczeniu objawów z dolnego odcinka układu moczowego, łagodnego przerostu prostaty, zaburzeń erekcji - Google Patents

Kompozycje i sposoby użyteczne w leczeniu objawów z dolnego odcinka układu moczowego, łagodnego przerostu prostaty, zaburzeń erekcji

Info

Publication number
PL3068414T3
PL3068414T3 PL14860917T PL14860917T PL3068414T3 PL 3068414 T3 PL3068414 T3 PL 3068414T3 PL 14860917 T PL14860917 T PL 14860917T PL 14860917 T PL14860917 T PL 14860917T PL 3068414 T3 PL3068414 T3 PL 3068414T3
Authority
PL
Poland
Prior art keywords
compositions
treatment
urinary tract
erectile dysfunction
benign prostatic
Prior art date
Application number
PL14860917T
Other languages
English (en)
Inventor
Emilie Annie Claudie Fromentin
Douglas Andrew Klaiber
Daniel David Souza
Original Assignee
Naturex Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53042226&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3068414(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Naturex Inc. filed Critical Naturex Inc.
Publication of PL3068414T3 publication Critical patent/PL3068414T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL14860917T 2013-11-11 2014-11-11 Kompozycje i sposoby użyteczne w leczeniu objawów z dolnego odcinka układu moczowego, łagodnego przerostu prostaty, zaburzeń erekcji PL3068414T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361902376P 2013-11-11 2013-11-11
EP14860917.5A EP3068414B1 (en) 2013-11-11 2014-11-11 Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction
PCT/US2014/064961 WO2015070203A1 (en) 2013-11-11 2014-11-11 Compositions and methods useful in treatment of lower urinary tract sysptoms, benign prostatic hyperplasia, erectile dysfunction

Publications (1)

Publication Number Publication Date
PL3068414T3 true PL3068414T3 (pl) 2021-08-30

Family

ID=53042226

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14860917T PL3068414T3 (pl) 2013-11-11 2014-11-11 Kompozycje i sposoby użyteczne w leczeniu objawów z dolnego odcinka układu moczowego, łagodnego przerostu prostaty, zaburzeń erekcji

Country Status (21)

Country Link
US (5) US20160324911A1 (pl)
EP (2) EP3782634B1 (pl)
JP (2) JP6966196B2 (pl)
KR (2) KR20230004886A (pl)
CN (2) CN105848663A (pl)
AU (1) AU2014346415B2 (pl)
BR (1) BR112016010509B1 (pl)
CA (1) CA2928631A1 (pl)
CL (1) CL2016001109A1 (pl)
CR (1) CR20160254A (pl)
ES (1) ES2860773T3 (pl)
IL (1) IL245552B (pl)
MX (1) MX2016005810A (pl)
MY (1) MY184225A (pl)
NZ (1) NZ719268A (pl)
PH (1) PH12016500780A1 (pl)
PL (1) PL3068414T3 (pl)
RU (1) RU2696584C1 (pl)
SG (2) SG10201910781SA (pl)
WO (1) WO2015070203A1 (pl)
ZA (1) ZA201602941B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016010509B1 (pt) * 2013-11-11 2021-08-17 Naturex-Dbs Llc Usos de uma forma de dosagem oral sólida
WO2018134962A1 (ja) * 2017-01-20 2018-07-26 マルカイコーポレーション株式会社 頻尿の改善剤
CN107647387A (zh) * 2017-08-15 2018-02-02 孟广千 用于补膀胱的保健食品
IT201800007473A1 (it) 2018-07-24 2020-01-24 Sistema di aggancio ad evidenza di manomissione, procedimento per la realizzazione di detto sistema di aggancio, contenitore comprendente detto sistema di aggancio ed uso di quest'ultimo
JP7219907B2 (ja) * 2018-07-25 2023-02-09 株式会社 沖縄リサーチセンター 下部尿路症状改善用組成物
JP6738388B2 (ja) * 2018-09-27 2020-08-12 マルカイコーポレーション株式会社 頻尿の改善剤
JP7400098B2 (ja) * 2019-11-08 2023-12-18 シージェイ チェイルジェダン コーポレーション ポリフェノールを含む組成物
WO2022045846A1 (ko) * 2020-08-31 2022-03-03 건국대학교 글로컬산학협력단 미선나무 추출물을 유효성분으로 포함하는 안드로겐 수용체 관련 질환 치료용 약학적 조성물
WO2022189010A1 (en) * 2021-03-07 2022-09-15 Givaudan Sa Methods and compositions for treating and preventing urinary tract infections
KR102388984B1 (ko) * 2021-11-16 2022-04-20 재단법인 전남바이오산업진흥원 모새나무 열매 추출물을 유효성분으로 포함하는 전립선 비대증 예방 또는 치료용 약학조성물

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5525341A (en) * 1992-10-09 1996-06-11 Jlb, Inc. Partially purified cranberry anti-adhesion activity
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6231866B1 (en) * 1998-04-30 2001-05-15 Douglas G. Mann Infused vegetable, fruit, herb, and/or seed fiber product and dietary supplements containing same
US20010025059A1 (en) 2000-01-10 2001-09-27 Kastke Floyd A. Composition and method for treating non-bacterial prostatitis
US6391345B1 (en) 2000-05-12 2002-05-21 Tim Heeg Cranberry seed oil, cranberry seed flour and a method for making
JP2001342142A (ja) * 2000-06-01 2001-12-11 Nissui Pharm Co Ltd 泌尿器系疾患予防治療用組成物
US7270837B2 (en) * 2003-11-10 2007-09-18 Rutgers, The State University Of New Jersey Anti-inflammatory cranberry flavonol extract preparations
EP1727522A2 (en) * 2004-02-04 2006-12-06 Foamix Ltd. Cosmetic and pharmaceutical foam with solid matter
JP2008500027A (ja) * 2004-05-03 2008-01-10 ノーザン ライツ フード プロセシング，エルエルシー ベリーオイルおよび製品
US8153166B2 (en) * 2006-06-08 2012-04-10 Chih-Hsiung Lin Composition for prophylaxis or treatment of urinary system infection and method thereof
JP2010531174A (ja) * 2007-06-27 2010-09-24 コロプラスト アクティーゼルスカブ サポニンと抗生物質の混合物による尿路感染症の治療
CN101095764B (zh) * 2007-07-13 2010-05-19 天津天狮生物发展有限公司 具有辅助治疗女性泌尿道感染的保健食品
US8173178B1 (en) 2007-08-03 2012-05-08 Decas Botanical Synergies, Llc Compositions and methods for controlling metabolic syndrome using whole fruit-derived cranberry ingredient profile enriched in stress adapted bioactives (SABs)
US20090175843A1 (en) * 2008-01-08 2009-07-09 Medical Nutrition Usa, Inc. Composition for prevention or treatment of urinary tract infection
US20090180999A1 (en) * 2008-01-11 2009-07-16 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections using cranberry derivative and d-mannose composition
US20110064706A1 (en) 2008-01-11 2011-03-17 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections and supporting digestive health by using a synergistic cranberry derivative, a d-mannose composition and a proprietary probiotic blend
EP2156835A1 (en) * 2008-08-19 2010-02-24 Sanofi-Aventis New therapeutic use of drotaverine
WO2011088420A1 (en) 2010-01-15 2011-07-21 Ocean Spray Cranberries, Inc. Process for extracting compound from cranberry leaves and related products
CN101999648B (zh) * 2010-10-11 2012-10-31 宝鸡市虹源生物科技有限公司 蔓越橘果实中花色苷及原花青素类成分的提取方法
JP2012171899A (ja) * 2011-02-21 2012-09-10 Unitika Ltd 尿路感染症予防改善剤
FR2972328A1 (fr) * 2011-03-07 2012-09-14 Walmark A S Complement alimentaire augmentant la protection de l'epithelium des voies urinaires basses contre les infections a repetition
US20130122146A1 (en) * 2011-11-16 2013-05-16 Decas Botanical Synergies, Llc Process for Spray Drying Botanical Food
BR112016010509B1 (pt) * 2013-11-11 2021-08-17 Naturex-Dbs Llc Usos de uma forma de dosagem oral sólida

Also Published As

Publication number Publication date
KR20160079884A (ko) 2016-07-06
CN105848663A (zh) 2016-08-10
JP2020059725A (ja) 2020-04-16
EP3068414A1 (en) 2016-09-21
NZ719268A (en) 2021-07-30
PH12016500780B1 (en) 2016-06-13
US11291703B2 (en) 2022-04-05
IL245552A0 (en) 2016-06-30
WO2015070203A1 (en) 2015-05-14
US10898534B2 (en) 2021-01-26
SG11201603462SA (en) 2016-05-30
WO2015070203A9 (en) 2016-01-14
KR20230004886A (ko) 2023-01-06
US20160324911A1 (en) 2016-11-10
IL245552B (en) 2020-07-30
EP3782634A1 (en) 2021-02-24
RU2696584C1 (ru) 2019-08-05
BR112016010509B1 (pt) 2021-08-17
RU2016122062A (ru) 2017-12-19
KR102476969B1 (ko) 2022-12-12
EP3068414A4 (en) 2017-06-07
EP3068414B1 (en) 2020-12-30
ES2860773T3 (es) 2021-10-05
ZA201602941B (en) 2022-05-25
JP6966196B2 (ja) 2021-11-10
AU2014346415B2 (en) 2020-04-23
MX2016005810A (es) 2016-11-18
US20180256663A1 (en) 2018-09-13
US20190358282A1 (en) 2019-11-28
PH12016500780A1 (en) 2016-06-13
CN116077548A (zh) 2023-05-09
CL2016001109A1 (es) 2016-12-02
SG10201910781SA (en) 2020-01-30
US20200121750A1 (en) 2020-04-23
MY184225A (en) 2021-03-28
JP2016539183A (ja) 2016-12-15
CA2928631A1 (en) 2015-05-14
JP7083330B2 (ja) 2022-06-10
US11045511B2 (en) 2021-06-29
BR112016010509A2 (pt) 2017-08-08
EP3782634B1 (en) 2024-03-20
CR20160254A (es) 2016-08-31
AU2014346415A1 (en) 2016-05-12
US20220175863A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
IL245552B (en) Compositions and methods useful for treating symptoms of the lower urinary tract, benign prostatic hyperplasia and impotence
HK1220995A1 (zh) 基於微生物的廢水處理組合物及其使用方法
IL244665A0 (en) Conjugates of chlorotoxin and methods of using them
IL273090B (en) Methods and preparations for the treatment of cancer
EP3618914A4 (en) IMPLANTABLE DEVICES AND TREATMENT METHODS FOR BENIGN PROSTATE HYPERPLASIA (BPH) AND ASSOCIATED LOWER URINARY TRACT SYMPTOMS (LUTS)
EP2675469A4 (en) COMPOSITIONS, DEVICES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER
EP2950807A4 (en) COMPOSITIONS AND METHOD FOR USE IN THE TREATMENT OF METABOLISM DISEASES
EP2831001A4 (en) COMPOSITION FOR THE TREATMENT OF WATER AND METHOD FOR USE
AP2011005943A0 (en) Atropisomers of 2-purinyl-3-tolylquinazolinone derivatives and methods of use.
EP3061459A4 (en) Composition for treating and preventing benign prostatic hyperplasia
GB201320723D0 (en) Composition and methods of treatment
EP2658551A4 (en) TREATMENT OF DYSERECTION AND OTHER INDICATIONS
LT3324994T (lt) Nx-1207, skirtas panaudoti chirurgijos poreikio sumažinimo metode pacientams, sergantiems gerybine prostatos hiperplazija
HK1209792A1 (en) Use of markers in the diagnosis and treatment of prostate cancer
ZA201109513B (en) Composition for the treatment of benign prostate hyperplasia
WO2012073047A3 (en) Compositions and methods
EP2908136A4 (en) METHOD AND KIT FOR THE DISTINCTION BETWEEN A PROSTATE CARCINOMA AND BENIGNER PROSTATE HYPERPLASIA
SG11201509738RA (en) Methods of treatment and compositions with xanthine oxidase inhibitors
IL233875A (en) Preparation and use for the treatment of anal fissures
GB2479693B (en) Steroidal CYP17 inhibitors and their use in the treatment of cancer and prostate hyperplasia
PL2575973T3 (pl) Polisacharyd z nasion tamaryndowca i ekstrakt z Ferula hermonis do zastosowania w leczeniu chorób zapalnych
EP2968374A4 (en) METHODS AND COMPOSITIONS FOR IMPROVING OXYGEN RATE IN FABRICS
EP2800568A4 (en) COMPOSITIONS, USE METHOD AND TREATMENT METHOD THEREFOR
EP2585109A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING ORGAN DAMAGE AND / OR DYSFUNCTION
DK2916856T4 (da) Anvendelser af bremelanotid til behandling af seksuel dysfunktion hos kvinder